Xcout IntelBolt Biotherapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Bolt Biotherapeutics, Inc. among biotech companies — ranked by similarity to what Bolt Biotherapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Bolt Biotherapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Bolt Biotherapeutics, Inc. at a glance
Bolt Biotherapeutics, Inc. is a biotech company headquartered in Redwood City, United States. It is publicly listed (BOLT) with a market capitalisation of $7.9M. Xcout tracks 15 named people at Bolt Biotherapeutics, Inc., including William Quinn (Chief Executive Officer, Chief Financial Officer, President, Secretary & Director).
Bolt Biotherapeutics, Inc. leadership
- William QuinnChief Executive Officer, Chief Financial Officer, President, Secretary & Director
- Willie QuinnChief Executive Officer
- Grant YonehiroChief Operating Officer & Chief Business Officer
- Michael N. Alonso, Ph.D.SVP, Research
- Michael N. AlonsoSenior Vice President of Research
- Sarah NemecSenior Vice President of Finance & Principal Accounting Officer
9 more named people on record for Bolt Biotherapeutics, Inc., with roles, board committees and tenure — see the full roster →
Bolt Biotherapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $93.5M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Bolt Biotherapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Bolt Biotherapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Boston Immune Technologies and Therapeutics, Inc. (BITT) is a company headquartered in Winchester, Massachusetts, that specializes in the development of cancer treatments and therapeutics.
Similar biotech company
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Biotechnology
Lurex Bio is an early-stage biotechnology research company developing a therapeutic platform designed to help the immune system recognize immune-cold solid tumors, such as MSS colorectal and pancreatic cancers. The company's proposed approach aims to mark tumor surfaces with synthetic recognition signals to make them more targetable by downstream immunotherapies.
Similar biotech company
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
Similar biotech company
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Similar biotech company
Coherus BioSciences, Inc. is a biopharmaceutical company headquartered in Redwood City, California, focused on oncology and developing innovative therapeutics.
Biotechnology
Bolden Therapeutics, Inc. is a privately held biotechnology company founded in 2019 and headquartered in Providence, Rhode Island, with corporate office space in Boston, Massachusetts. The company is dedicated to developing first-in-class therapeutics.
Biotechnology
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Biotechnology
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
Biotechnology
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Biotechnology
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Similar biotech company
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Bolt Biotherapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Bolt Biotherapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →